Rallybio (RLYB) announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic clinical trial evaluating RLYB116, the company's once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediated diseases with its initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. A 300 mg once-a-week dose of subcutaneously administered RLYB116 achieved complete and sustained inhibition of terminal complement.
"Based on our prior clinical experience, the Phase 1 results are compelling and provide strong corroboration for our scientific and clinical rationale," said Steven Ryder, Chief Medical Officer of Rallybio.
In pre-market trading on NasdaqCM, Rallybio shares are down 5.81 percent to $4.54.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.